Bulletin
Investor Alert

LogicBio Therapeutics Inc.

NAS: LOGC

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Mar 5, 2021, 7:09 p.m.

/zigman2/quotes/206745651/composite

$

8.96

Change

+1.32 +17.28%

Volume

Volume 3,472

Quotes are delayed by 20 min

/zigman2/quotes/206745651/composite

Previous close

$ 7.84

$ 7.64

Change

-0.20 -2.55%

Day low

Day high

$6.86

$7.83

Open

52 week low

52 week high

$3.05

$10.00

Open

Insider Actions for LogicBio Therapeutics Inc.

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/01/2021 Mark A. Kay
Director
2,199   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2021 Leon E. Chen
Director
3,298   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2021 Richard A. Moscicki
Director
3,916   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2021 Michael S. Wyzga
Director
3,141   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2021 Mark J. Enyedy
Director
2,921   Derivative/Non-derivative trans. at $0 per share. 0
12/10/2020 Daniel O’Connell
Director
2,513   Derivative/Non-derivative trans. at $0 per share. 0
09/25/2020 Arix Bioscience Plc
174,219   Disposition at $7.08 per share. 1,233,470
09/24/2020 Arix Bioscience Plc
38,514   Disposition at $7.63 per share. 293,861
08/13/2020 Arix Bioscience Plc
159   Disposition at $8.75 per share. 1,391
08/12/2020 Arix Bioscience Plc
1,335   Disposition at $8.79 per share. 11,734
07/29/2020 Arix Bioscience Plc
2,709   Disposition at $8.78 per share. 23,785
07/22/2020 Arix Bioscience Plc
22,651   Disposition at $9 per share. 203,859
07/20/2020 Arix Bioscience Plc
36,983   Disposition at $9.25 per share. 342,092
07/17/2020 Arix Bioscience Plc
31,101   Disposition at $9.24 per share. 287,373

Transaction Summary

Total insider purchases and sales reported to the SEC

Timeframe Transactions Shares
Last 3 months
6 Purchases
0 Sales
17,988
0
Last 6 months
6 Purchases
2 Sales
17,988
212,733
Last 12 months
6 Purchases
9 Sales
17,988
324,003

Officers and Executives

Dr. Richard A. Moscicki
Chairman
Mr. Frédéric Chéreau
President, Chief Executive Officer & Director
Dr. Kyle Chiang
Chief Operating Officer
Mr. Jonathan Quick
Senior Finance Director
Ms. Cecilia Jones
Chief Financial Officer
Dr. Daniel J. Gruskin
Senior Vice President & Head-Clinical Development
Dr. Mariana Nacht
Chief Scientific Officer
Dr. Matthias Hebben
Global VP & Head-Technology Development
Mr. J. Jeffrey Goater
Director
Ms. Daphne Karydas
Director
Mr. Brian Luque
Director- Investor Relations
Mr. Mark J. Enyedy
Independent Director
Dr. Leon E. Chen
Independent Director
Dr. Mark A. Kay
Independent Director
Mr. Michael S. Wyzga
Independent Director
Link to MarketWatch's Slice.